Michael Wallington
YOU?
Author Swipe
View article: Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States
Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States Open
Introduction: Standard of care (SOC) first line (1L) therapy for diffuse large B-cell lymphoma (DLBCL) includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and polatuzumab vedotin plus R-CHP (Pola-R-CHP),…
View article: Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: A national registry study
Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: A national registry study Open
Background: Survival from cancer in older patients is poorer in the UK than other countries with similar health systems and wealth possibly due to undertreatment and increased toxicities in this specific population. This population-based o…
30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study Open
Public Health England.